CompletedPhase 4

Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease

China50 participantsStarted 2019-07-02

Plain-language summary

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. Therefore, the investigators performed this study to observe the efficacy of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:• * Aged ≥18 years * Subjects had documented with stable CAD * Women were required to be postmenopausal or surgically sterile * Patients were required to discontinue clopidogrel or ticagrelor at least 14 days before randomization * Patients were required to discontinue aspirin at least 14 days before randomization. Exclusion Criteria: * Acute coronary syndrome * Planned use of glycoprotein IIb/IIIa receptor inhibitors, adenosine diphosphate (ADP) receptor antagonists other than the study medication, or anticoagulant therapy during the study period * Platelet count \<10×10\^4/μL * Hstory of bleeding tendency * Diagnosed as respiratory or circulatory instability * Allergy to ticagrelor or clopidogrel

What they're measuring

The platelet inhibition ratio

Timeframe: up to 3 months

Trial details

NCT IDNCT04001894

SponsorFirst Affiliated Hospital of Harbin Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-09

View on ClinicalTrials.gov More Platelet Reactivity trials